Novartis Aktie
91,74
EUR
+0,86
EUR
+0,95
%
86,14
CHF
+0,76
CHF
+0,89
%
Diese Analysten bewerten die Novartis-Aktie
Analyst | Kursziel | Abstand Kursziel | Datum | |
---|---|---|---|---|
Deutsche Bank AG | 110,00 CHF | - | 30.11.2023 | |
Barclays Capital | 85,00 CHF | - | 29.11.2023 | |
UBS AG | 90,00 CHF | - | 28.11.2023 | |
Jefferies & Company Inc. | 100,00 CHF | - | 28.11.2023 | |
Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 74,00 CHF | - | 19.10.2023 | |
JP Morgan Chase & Co. | 90,00 CHF | - | 05.10.2023 | |
Morgan Stanley | 98,00 CHF | - | 25.09.2023 | |
Credit Suisse Group | 90,00 CHF | - | 26.04.2023 | |
Goldman Sachs Group Inc. | 106,00 CHF | - | 13.02.2023 | |
Bernstein Research | 90,00 CHF | - | 08.12.2022 |
Kursziele im Branchenvergleich
Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
---|---|---|---|---|---|
Abbott Laboratories | 0 | 0 | 0 | - | - |
Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
Allergan Inc. | 0 | 0 | 0 | - | - |
APONTIS PHARMA | 0 | 0 | 0 | - | - |
AstraZeneca PLC | 5 | 2 | 1 | 119,06 GBP | - |
Bayer | 4 | 7 | 0 | 55,10 EUR | +77,86% |
Celgene Corp. | 0 | 0 | 0 | - | - |
EVOTEC SE | 2 | 2 | 0 | 25,40 EUR | +39,71% |
Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
GSK PLC Registered Shs | 3 | 3 | 2 | 15,87 GBP | - |
Johnson & Johnson | 0 | 0 | 0 | - | - |
Merck Co. | 0 | 0 | 0 | - | - |
Merck KGaA | 7 | 1 | 1 | 197,50 EUR | +22,29% |
Mylan N.V. | 0 | 0 | 0 | - | - |
Novartis AG | 3 | 5 | 2 | 93,30 CHF | - |
Pfizer Inc. | 3 | 4 | 0 | 41,14 USD | +39,93% |
Roche AG (Genussschein) | 3 | 5 | 2 | 291,78 CHF | - |
Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
Sanofi S.A. | 7 | 2 | 1 | 105,10 EUR | +21,70% |
STADA | 0 | 0 | 0 | - | - |
Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
Warner Chilcott plc | 0 | 0 | 0 | - | - |